| Identification | Back Directory | [Name]
(2S,4R)-1-(2-Aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid | [CAS]
943134-39-2 | [Synonyms]
ZP1609
ZP-1609
GAP-134
ZP 1609
Danegaptide
danegaptide,ZP1609
GAP-134 (Danegaptide)
Danegaptide free base
L-Proline, glycyl-4-(benzoylamino)-, (4R)-
DANEGAPTIDE;ZP1609;GAP134;GAP 134;ZP-1609;ZP 1609
(2S,4R)-4-benzamido-1-glycylpyrrolidine-2-carboxylic acid
(2S,4R)-1-(2-Aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid
(2S,4R)-1-(2-aminoacetyl)-4-benzoylaminopyrrolidine-2-carboxylic acid | [Molecular Formula]
C14H17N3O4 | [MDL Number]
MFCD16619374 | [MOL File]
943134-39-2.mol | [Molecular Weight]
291.3 |
| Chemical Properties | Back Directory | [Boiling point ]
642.4±55.0 °C(Predicted) | [density ]
1.38±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO | [form ]
Powder | [pka]
2.93±0.40(Predicted) |
| Hazard Information | Back Directory | [Uses]
Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect[1][2]. | [Definition]
ChEBI: Danegaptide is a dipeptide. | [in vivo]
Danegaptide (GAP-134, compound 9f) is evaluated for in vivo efficacy in the mouse CaCl2 model after oral administration. For doses of 5-20 mg/kg po, Danegaptide significantly prolongs the time to conduction block in mice after the infusion of CaCl2[1].
Danegaptide (GAP-134) is biologically active upon oral administration at an average plasma concentration of 250 nM, and reduces atrial fibrillation in a dog model. Danegaptide has no effect on heart rate, arterial blood pressure or other electrocardiogram (ECG) parameters. Danegaptide is an effective antiarrhythmic compound in the setting of ischaemia/reperfusion-induced arrhythmogenesis in barbiturate-anesthetized, open-chest beagles[2]. | [References]
[1] John A Butera, et al. Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation. J Med Chem. 2009 Feb 26;52(4): DOI:10.1021/jm801558d
[2] Elke De Vuyst, et al. Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. Br J Pharmacol. 2011 Jun;163(3):469-83. DOI:10.1111/j.1476-5381.2011.01244.x |
|
| Company Name: |
TaiChem Taizhou Limited
|
| Telephone: |
052386810091 |
| Website: |
https://www.chemicalbook.com/supplier/11410902/1.htm |
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|